Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.54 |
| ▸ | RAB9A | P51151 | 8/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9542349 | 1.00 | NPC1 (0.54) | NPC1RAB9AMAPTALOX5PSMB8 | |
| SCHEMBL824375 | 0.77 | NPC1 (0.69) | NPC1RAB9AMAPTALOX5PSMB8 | |
| SCHEMBL29531707 | 0.77 | NPC1 (0.69) | NPC1RAB9AMAPTALOX5PSMB8 | |
| SCHEMBL6445384 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTALOX5PSMB8 | |
| SCHEMBL10045305 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTALOX5PSMB8 | |
| SCHEMBL129661 | 0.71 | MAPT (0.59) | NPC1RAB9AMAPTALOX5PSMB8 | |
| SCHEMBL1280187 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTALOX5PSMB8 | |
| SCHEMBL6445389 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTALOX5PSMB8 | |
| SCHEMBL430870 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTALOX5PSMB8 | |
| SCHEMBL22190326 | 0.71 | NPC1 (0.54) | NPC1RAB9AMAPTALOX5PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0252713-B1 | INDOLINONE DERIVATIVES | PFIZER INC. (US) | 1990-09-12 | — | — | EP | claimed |
| EP-0252713-A1 | Indolinone derivatives | PFIZER INC. (US) | 1988-01-13 | — | — | EP | claimed |
| US-10388890-B2 | Organic electroluminescent heterocyclic carbene metal complexes and devices containing the same | UNIVERSAL DISPLAY CORPORATION (US) | 2019-08-20 | — | — | US | disclosed |
| US-20150188062-A1 | METHOD OF MAKING ORGANIC ELECTROLUMINESCENT MATERIALS | UNIVERSAL DISPLAY CORPORATION (US) | 2015-07-02 | — | — | US | disclosed |
| US-8748011-B2 | Ruthenium carbene complexes for OLED material | UNIVERSAL DISPLAY CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| WO-2012116240-A1 | RUTHENIUM CARBENE COMPLEXES FOR OLED MATERIAL | UNIVERSAL DISPLAY CORPORATION (US) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012116242-A1 | THIAZOLE AND OXOZOLE CARBENE METAL COMPLEXES AS PHOSPHORESCENT OLED MATERIALS | UNIVERSAL DISPLAY CORPORATION (US) | 2012-08-30 | — | — | WO | disclosed |
| US-20120212125-A1 | RUTHENIUM CARBENE COMPLEXES FOR OLED MATERIAL | UNIVERSAL DISPLAY CORPORATION | 2012-08-23 | — | — | US | disclosed |
| WO-1993012786-A1 | INDOLINONE DERIVATIVES | HOWARD HARRY R JR (US) | 1993-07-08 | — | — | WO | disclosed |
| US-5064852-A | Antidiabetic agents; aldose reductase inhibitors | PFIZER INC. (US) | 1991-11-12 | — | — | US | disclosed |
| US-4960785-A | Indolinone derivatives | PFIZER INC. (US) | 1990-10-02 | — | — | US | disclosed |
| EP-0252713-B1 | INDOLINONE DERIVATIVES | PFIZER INC. (US) | 1990-09-12 | — | — | EP | disclosed |
| EP-0252713-A1 | Indolinone derivatives | PFIZER INC. (US) | 1988-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120212125-A1 | RUTHENIUM CARBENE COMPLEXES FOR OLED MATERIAL | OCIAD2, OCIAD1, ORC3 | NPC1 1611/4885RAB9A 1966/4885MAPT 1293/4885 |
| US-10388890-B2 | Organic electroluminescent heterocyclic carbene metal complexes and devices containing the same | OXA1L, OXER1, OCIAD1 | NPC1 3239/4885RAB9A 4119/4885MAPT 1447/4885 |
| US-20150188062-A1 | METHOD OF MAKING ORGANIC ELECTROLUMINESCENT MATERIALS | OXA1L, OCIAD1, OXER1 | NPC1 2562/4885RAB9A 4291/4885MAPT 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.